CALGARY, ALBERTA--(CCNMatthews - Oct. 3, 2005) - Resverlogix Corp. (TSX:RVX), announced today preclinical findings on its lead cardiovascular technology program NEXVASTM. The announcement of these research findings comes from an expanding body of information illustrating the feasibility of small molecule ApoA1 enhancement in multiple animal models for the potential treatment of cardiovascular disease and the regression of atherosclerosis.
